

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1-11 (Canceled)

Claim 12 (Currently Amended): A method of claim [[4]] 20, wherein the said combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim. 13-14 (Canceled)

Claim 15 (Currently Amended): A method of claim [[4]] 20, wherein the dosage of androgen testosterone is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen dienogest is 20 µg to 20 mg.

Claim 16 (Currently Amended): A method of claim [[2]] 32, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claims 17-19 (Canceled)

*Presented*

Claim 20 (~~Currently Amended~~): A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia or a prostate cancer comprising administering to said patient a combination of testosterone and dienogest.

Claims 21-31 (Canceled)

Claim 32 (Currently Amended): ~~A method according to claim 1, wherein the~~ A method of compensating for an absolute or relative testosterone deficiency in a patient who has said

testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia or a prostate cancer comprising administering to said patient a combination of an androgenically effective amount of a natural or synthetic androgen, and a gestagenically effective amount of a gestagen which is dienogest.

Claim 33 (Currently Amended): ~~A method according to claim 1, wherein the gestagen component~~ A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia or a prostate cancer comprising administering to said patient a combination of an androgenically effective amount of a natural or synthetic androgen which is testosterone propionate, and a gestagenically effective amount of a gestagen which is dienogest, chloromadinone acetate or cyproterone acetate and the natural androgen component is testosterone propionate.

Claim 34 (Canceled)

Claim 35 (Previously Presented): A method according to claim 33, wherein prophylaxis for the development of a benign prostatic hyperplasia is achieved.

Claim 36-37 (Canceled)

Claim 38 (New): A method of claim 32, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 39 (New): A method of claim 33, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 40 (New): A method of claim 33, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 41 (New): A method of claim 35, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 42 (New): A method of claim 35, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 43 (New): A method according to claim 33, wherein prophylaxis for the development of a prostate cancer is achieved.

Claim 44 (New): A method according to claim 33, wherein the gestagen is dienogest.

Claim 45 (New): A method according to claim 33, wherein the gestagen is chloromadinone acetate.

Claim 46 (New): A method according to claim 33, wherein the cyproterone acetate.

Claim 47 (New): A method according to claim 32, wherein a natural androgen is administered.

Claim 48 (New): A method according to claim 32, wherein a synthetic androgen is administered.

Claim 49 (New): A method of claim 43, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 50 (New): A method of claim 43, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 51 (New): A method of claim 44, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 52 (New): A method of claim 44, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 53 (New): A method of claim 45, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 54 (New): A method of claim 45, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 55 (New): A method of claim 46, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 56 (New): A method of claim 46, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 57 (New): A method of claim 47, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 58 (New): A method of claim 47, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 59 (New): A method of claim 48, wherein the combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 60 (New): A method of claim 48, wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.